Balancing Quality of Life: Adjuvant Therapy Toxicity in Melanoma Adjuvant Immunotherapy

EP: 1.An Overview of the Landscape Surrounding Melanoma

EP: 2.The Role of Biomarker Testing in Melanoma

EP: 3.The Current Landscape Surrounding Adjuvant Therapy in Melanoma

EP: 4.Combination Immunotherapy Strategies for Melanoma in the Adjuvant Setting

EP: 5.Navigating Challenges in Predicting and Mitigating Adverse Events in Adjuvant Immunotherapy

EP: 6.Exploring Immunotherapy Resistance: Impact on Treatment Decisions in Melanoma

Now Viewing

EP: 7.Balancing Quality of Life: Adjuvant Therapy Toxicity in Melanoma Adjuvant Immunotherapy

EP: 8.Case 1: Man Aged 55 Years With Stage IIIB Melanoma Developing Immunotherapy-Induced Diabetes

EP: 9.Immunotherapy-Related Diabetes in Melanoma: A Management Perspective

EP: 10.Immunotherapy-Induced Adrenal Insufficiency in Melanoma: Surveillance and Management

EP: 11.Case 2: 63-Year-Old Female Patient With Metastatic Melanoma on Dual Immunotherapy Developing Treatment-Related Myocarditis

EP: 12.Approaches to Diagnosing and Managing Myocarditis Related to Immunotherapy

EP: 13.Expert Perspectives on Cardiac Baseline and Surveillance Testing in Immunotherapy Recipients

EP: 14.Corticosteroid Treatment Challenges in Patients with Immunotherapy-Related Toxicities

EP: 15.Forward Outlook and Clinical Insights in Melanoma Treatment

This is a video synopsis/summary of an OncLive Insights^® involving Afreen Shariff, MD, MBBS; Javid Moslehi, MD; and Nikhil Khushalani, MD.

This segment discusses balancing quality of life and potential toxicity risks against possibility of cure with adjuvant therapy vs surgery alone for patients with lower-risk melanoma. Khushalani notes that 10% to 18% of patients have grade 3 or higher immune-related adverse events with adjuvant anti–PD-1 therapy, which is not trivial, especially in older patients with comorbidities. Such patients with minimal stage IIIA disease can often be safely observed after surgery without adjuvant treatment given good inherent outcomes.

Even within stage IIIA cohorts, central lymph node disease burden is being used to refine risk stratification, with very low-volume disease increasingly seen as having favorable enough prognosis to potentially omit adjuvant therapy. Khushalani emphasizes thoroughly discussing patient-specific factors such as age and comorbidities as part of a shared decision-making process regarding adjuvant therapy risks/benefits.

Video synopsis is AI generated and reviewed by OncLive^® editorial staff.